Down-titration of Steroids in Patients With Difficult Asthma With no Bronchial Hyperreactivity

• Status: Completed
• Trial end date: 2017-05-31
• Target enrollment: 0
• Participant gender: All

Summary

An 8 week 'real-life' inhaled corticosteroid (ICS) dose reduction study in patients with severe asthma without evidence of bronchial hyperactivity.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bispebjerg Hospital

Criteria

Inclusion Criteria:

• Physician-diagnosed asthma for at least 6 months

• Fulfill ERS/ATS giudelines for severe asthma

• Stable dose of ICS for at least 4 weeks

• Able to carry out study procedures

• Negative metacholine provocation test at screening

• Negative reversibility to beta agonist at screening

• FeNO under 50 ppb

Exclusion Criteria:

• Treatment with prednisolone, methotrexate, ciclosporin, omalizumab or nucala in the last 6 months

• FEV1 under 70% of predicted

• Acute upper or lower airway infection requiring antibiotics in the last 4 weeks

• Exacerbation of asthma requiring prednisolone in the last 6 months

• Current smoking

• Pregnancy or breastfeeding

• Other clinically significant lung disease

• Current participation in another interventional study